✦ LIBER ✦

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

✍ Scribed by Francis J. Giles; Alan F. List; Michael Carroll; Jorge E. Cortes; Joyce Valickas; Bee-Lian Chen; Eric Masson; Christian Jacques; Dirk Laurent; Maher Albitar; Eric J. Feldman; Gail J. Roboz

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 151 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2006.12.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biomarkers for assessment of pharmacolog

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases

✍ Lucy Lee; Sunil Sharma; Bruno Morgan; Peter Allegrini; Christian Schnell; Josef 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 427 KB

PTK787/ZK222584, a tyrosine kinase inhib

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

✍ Markus Rudin; Paul M. J. McSheehy; Peter R. Allegrini; Martin Rausch; Diana Baum 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 793 KB

## Abstract Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti‐angiogenic therapy. Non‐invasive measurement of tumour perfusion and blood vessel permeability assessed as the transfer constant, __K__^trans^, can be provided by dynamic contrast‐enha

Phase II study of SU5416—a small-molecul

Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

✍ Francis J. Giles; Maureen A. Cooper; Lewis Silverman; Judith E. Karp; Jeffrey E. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myeloid leukemia in blastic phase (CML